Improvement of motor function in early Parkinson disease by safinamide.
about
Monoamine oxidase B inhibitors for early Parkinson's diseaseAvailable and emerging treatments for Parkinson's disease: a reviewEmerging approaches in Parkinson's disease - adjunctive role of safinamideAdjuvant therapies for Parkinson's disease: critical evaluation of safinamideTherapy for Parkinson's disease: what is in the pipeline?Inhibitors of MAO-A and MAO-B in Psychiatry and NeurologyNew small molecules for the treatment of Parkinson's disease.The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.Emerging drugs for Parkinson's disease.Drug Insight: new drugs in development for Parkinson's disease.An update on pharmacological approaches to neurodegenerative diseases.Functional Magnetic Resonance Imaging Neurofeedback-guided Motor Imagery Training and Motor Training for Parkinson's Disease: Randomized TrialNew approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins.How should we treat a patient with early Parkinson's disease?Safinamide in the treatment of Parkinson's disease.Therapies for dopaminergic-induced dyskinesias in Parkinson disease.Future treatments for Parkinson's disease: surfing the PD pipeline.Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.Ascertainment bias in dementias: a secondary to tertiary centre analysis in Central Italy and conceptual review.Current status of safinamide for the drug portfolio of Parkinson's disease therapy.Safinamide for the treatment of Parkinson's disease.Safinamide: first global approval.Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease.Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.Clinical Pharmacokinetics and Pharmacodynamics of Safinamide.Investigational agents in the treatment of Parkinson's disease: focus on safinamide.Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson's disease.Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.Established therapies and novel targets in the treatment of Parkinson's disease.Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease.Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.Formulary Drug Review: Safinamide.Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers.Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence
P2860
Q24246514-E9C0B784-D3AA-44AC-9A6A-AD282BB2C9C0Q24633444-22F70F0E-2CD4-4C7D-8FC5-553A1FAD9D2BQ26740905-B695C414-6D85-4987-A110-8185B2F1F707Q26766289-3308CC08-2688-4488-947B-FE00E8202F06Q26991826-9C9C313E-5994-4A60-BCA6-D325F8EFC678Q28069609-A6329586-4C9D-4535-B34F-C454DA4E666CQ33636631-024B4447-0E65-476A-8051-9ECF58612348Q34512544-9C525506-1396-49E3-BCA1-11F1523B40B0Q34853030-56C1FAF9-C91D-4AEA-BE44-71720B5F3546Q36580572-326302E1-669A-409C-96B4-2484D60D0CCAQ36631654-CF4AA751-C55D-4646-821D-F670C2D7E48CQ36677402-986F3EAB-CD4A-4768-A598-E13283409314Q36978670-F7FB0E4A-B2C0-46CF-A93E-577DC48B22BAQ37021326-478FAB71-A404-4561-BB0A-2BF566406FA8Q37775098-8338AFFD-7349-472E-B5B0-F92E9943EAC6Q37779808-E09527A4-45B4-4F07-925A-F2C065D8A5FDQ37890986-AC8658BA-4993-4AB2-B61A-908B431DF9F7Q37950428-F5D4B78D-2C72-4115-87E0-3B43C7AD5715Q37963572-B8BC0130-1ABC-4242-938D-ADF2B163411DQ38115735-B3BC2F95-AD48-42D6-A15C-6F7F64F6EF4CQ38140018-ED831C8D-9C39-4E7B-8400-FAFB43C2935CQ38197710-112873A5-25EC-4097-B912-2E0E0FA56074Q38410199-3CF25EFE-944A-429A-AA2A-9AF2EB568B59Q38545359-094A045E-DB96-4ABE-B0D8-D11EDD69839BQ38640108-AC1B252E-B63D-4FC4-9157-FCE0C379F274Q38817972-25E75047-D155-4C76-A109-BCB26BB19DC3Q38836062-66B8525A-133B-495A-AC31-68AD1CF95668Q41645312-7CE82BE5-BD94-4D9C-A14D-ECF3113C61EAQ42531922-01383594-8E6F-4254-9FA6-ECC98FCA53C3Q42723595-E101B850-61F7-4406-96D7-14328C1EE664Q43620394-0EBA84E2-CD0F-490B-A464-B5418B04B038Q48250410-86A1D169-2991-4216-9749-084AB6091107Q49587005-D3F07EB1-9B65-49C4-96A6-D2150F284098Q51369362-3C499BAD-EA5E-4065-9F2F-FBC996139F7DQ57074141-53C4FCB9-6DEE-48A2-92AB-F2FC781A16C3
P2860
Improvement of motor function in early Parkinson disease by safinamide.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Improvement of motor function in early Parkinson disease by safinamide.
@en
Improvement of motor function in early Parkinson disease by safinamide.
@nl
type
label
Improvement of motor function in early Parkinson disease by safinamide.
@en
Improvement of motor function in early Parkinson disease by safinamide.
@nl
prefLabel
Improvement of motor function in early Parkinson disease by safinamide.
@en
Improvement of motor function in early Parkinson disease by safinamide.
@nl
P2093
P1433
P1476
Improvement of motor function in early Parkinson disease by safinamide.
@en
P2093
A Szczudlik
A Van Dijk
C Cattaneo
H Kwiecinski
R G Fariello
Safinamide Parkinson's Study Group
P304
P356
10.1212/01.WNL.0000134672.44217.F7
P407
P577
2004-08-01T00:00:00Z